CPRX Stock Overview
A commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community Narratives
Narratives bring a range of perspectives from our community.
Successful Product Expansions And Global Partnerships Fuel Revenue Surge And Profit Growth
Catalyst Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.29 |
| 52 Week High | US$20.87 |
| 52 Week Low | US$11.55 |
| Beta | 0.76 |
| 11 Month Change | 3.57% |
| 3 Month Change | 34.73% |
| 1 Year Change | 58.39% |
| 33 Year Change | 308.25% |
| 5 Year Change | 208.83% |
| Change since IPO | 232.62% |
Recent News & Updates
Recent updates
Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)
Jul 24
Catalyst Pharmaceuticals: New Products In Proving Phase
Jul 06Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)
Apr 06Earnings Tell The Story For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)
Jan 29Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk
Jan 17With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case
Sep 06Should You Be Adding Catalyst Pharmaceuticals (NASDAQ:CPRX) To Your Watchlist Today?
May 27Do Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Warrant Your Attention?
Feb 13Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist?
Nov 11Catalyst Pharmaceuticals gains 9% on SmallCap 600 addition
Sep 12Catalyst Pharma ends momentum as Roth downgrades
Aug 24Shareholder Returns
| CPRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.4% | 2.3% | 1.6% |
| 1Y | 58.4% | 15.9% | 22.0% |
Return vs Industry: CPRX exceeded the US Biotechs industry which returned 15.9% over the past year.
Return vs Market: CPRX exceeded the US Market which returned 22% over the past year.
Price Volatility
| CPRX volatility | |
|---|---|
| CPRX Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CPRX's share price has been volatile over the past 3 months.
Volatility Over Time: CPRX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 167 | Rich Daly | www.catalystpharma.com |
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type.
Catalyst Pharmaceuticals, Inc. Fundamentals Summary
| CPRX fundamental statistics | |
|---|---|
| Market cap | US$2.31b |
| Earnings (TTM) | US$68.15m |
| Revenue (TTM) | US$434.48m |
35.3x
P/E Ratio5.5x
P/S RatioIs CPRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CPRX income statement (TTM) | |
|---|---|
| Revenue | US$434.48m |
| Cost of Revenue | US$151.27m |
| Gross Profit | US$283.20m |
| Other Expenses | US$215.05m |
| Earnings | US$68.15m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.57 |
| Gross Margin | 65.18% |
| Net Profit Margin | 15.69% |
| Debt/Equity Ratio | 0% |
How did CPRX perform over the long term?
See historical performance and comparison